Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Polymeric strontium ranelate nona-hydrate.

ABSTRACT: The title compound, poly[[μ-aqua-tetra-aqua{μ-5-[bis-(carboxyl-atometh-yl)amino]-3-carboxyl-atomethyl-4-cyano-thio-phene-2-carboxyl-ato}distrontium(II)] tetra-hydrate], [Sr(2)(C(12)H(6)N(2)O(8)S)(H(2)O)(5)]·3.79H(2)O, crystallizes with nine- and eight-coordinated Sr(2+) cations. They are bound to seven of the eight ranelate O atoms and five of the water mol-ecules. The SrO(8) and SrO(9) polyhedra are inter-connected by edge-sharing, forming hollow layers parallel to (011). The layers are, in turn, inter-connected by ranelate anions, forming a metal-organic framework (MOF) structure with channels along the a axis. The four water mol-ecules not coordinated to strontium are located in these channels and hydrogen bonded to each other and to the ranelates. Part of the water H atoms are disordered. The compound dehydrates very easily and 0.210 (4) water mol-ecules out of nine were lost during crystal mounting causing additional disorder in the water structure.

SUBMITTER: Stahl K

PROVIDER: S-EPMC3099985 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Polymeric strontium ranelate nona-hydrate.

Stahl Kenny K Frankaer Christian G CG Raffalt Anders C AC Sørensen Søren R SR Andersen Jens E T JE

Acta crystallographica. Section E, Structure reports online 20110323 Pt 4

The title compound, poly[[μ-aqua-tetra-aqua{μ-5-[bis-(carboxyl-atometh-yl)amino]-3-carboxyl-atomethyl-4-cyano-thio-phene-2-carboxyl-ato}distrontium(II)] tetra-hydrate], [Sr(2)(C(12)H(6)N(2)O(8)S)(H(2)O)(5)]·3.79H(2)O, crystallizes with nine- and eight-coordinated Sr(2+) cations. They are bound to seven of the eight ranelate O atoms and five of the water mol-ecules. The SrO(8) and SrO(9) polyhedra are inter-connected by edge-sharing, forming hollow layers parallel to (011). The layers are, in tur ...[more]

PMID: 21753986

Similar Datasets

Strontium ranelate for the treatment of osteoporosis.

Project description: Not available

| S-EPMC558360 | biostudies-literature

Strontium Ranelate Inhibits Osteoclastogenesis through NF-κB-Pathway-Dependent Autophagy.

Project description:Strontium ranelate (SR) is a pharmaceutical agent used for the prevention and treatment of osteoporosis and fragility fracture. However, little attention has been paid to the effect of SR on alveolar bone remodeling during orthodontic tooth movement and its underlying mechanism. Here, we investigated the influence of SR on orthodontic tooth movement and tooth resorption in Sprague-Dawley rats and the relationship between the nuclear factor-kappa B (NF-κB) pathway, autophagy, and osteoclastogenesis after the administration of SR in vitro and in vivo. In this study, it was found that SR reduced the expression of autophagy-related proteins at the pressure side of the first molars during orthodontic tooth movement. Similarly, the expression of these autophagy-related proteins and the size and number of autophagosomes were downregulated by SR in vitro. The results also showed that SR reduced the number of osteoclasts and suppressed orthodontic tooth movement and root resorption in rats, which could be partially restored using rapamycin, an autophagy inducer. Autophagy was attenuated after pre-osteoclasts were treated with Bay 11-7082, an NF-κB pathway inhibitor, while SR reduced the expression of the proteins central to the NF-κB pathway. Collectively, this study revealed that SR might suppress osteoclastogenesis through NF-κB-pathway-dependent autophagy, resulting in the inhibition of orthodontic tooth movement and root resorption in rats, which might offer a new insight into the treatment of malocclusion and bone metabolic diseases.

| S-EPMC10045081 | biostudies-literature

Crystal structure of penta-potassium di-hydrogen nona-vanadato(V)platinate(IV) nona-hydrate.

Project description:The title compound, K5[H2PtV9O28]·9H2O, containing the nona-vanado-platinate(IV) polyanion, was obtained by hydro-thermal reaction at pH = 4.2. The polyanion has approximate mm2 (C 2v ) symmetry. The two platinum-bound μ2-O atoms are protonated in the polyanion. The heteropolyanions form inversion-generated dimers, {[H2PtV9O28]2}(10-), held together by μ2-O-H⋯μ2-O and μ2-O-H⋯μ3-O hydrogen bonds. All K(+) cations are located on general positions of the space group P-1.

| S-EPMC4459313 | biostudies-literature

Crystal structure of iron(III) perchlorate nona-hydrate.

Project description:Since the discovery of perchlorate salts on Mars and the known occurrence of ferric salts in the regolith, there is a distinct possibility that the title compound could form on the surface of Mars. [Fe(H2O)6](ClO4)3·3H2O was crystallized from aqueous solutions at low temperatures according to the solid-liquid phase diagram. It consists of Fe(H2O)6 octa-hedra (point group symmetry -3.) and perchlorate anions (point group symmetry .2) as well as non-coordinating water mol-ecules, as part of a second hydrogen-bonded coordination sphere around the cation. The perchlorate appears to be slightly disordered, with major-minor component occupancies of 0.773 (9):0.227 (9).

| S-EPMC4257414 | biostudies-literature

Strontium Ranelate Ameliorates Intervertebral Disc Degeneration via Regulating TGF-β1/NF-κB Axis.

Project description:Intervertebral disc degeneration (IVDD) is a prevalent and debilitating condition characterized by chronic back pain and reduced quality of life. Strontium ranelate (SRR) is a compound traditionally used for treating osteoporosis via activating TGF-β1 signaling pathway. Recent studies have proved the anti-inflammatory effect of SRR on chondrocytes. Although the exact mechanism of IVDD remains unclear, accumulating evidences have emphasized the involvement of multifactorial pathogenesis including inflammation, oxidative stress damage, and etc. However, the biological effect of SRR on IVDD and its molecular mechanism has not been investigated. Firstly, this study proved the decreased expression of Transforming Growth Factor-beta 1(TGF-β1) in degenerated human intervertebral disc tissues. Subsequently, we confirmed for the first time that SRR could promote cell proliferation, mitigate inflammation and oxidative stress in human nucleus pulposus cells in vitro via increasing the expression of TGF-β1 and suppressing the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) pathway. The molecular docking result proved the interaction between SRR and TGF-β1 protein. To further verify this interaction, gain- and loss- of function experiments were conducted. We discovered that both TGF-β1 knockdown and overexpression influenced the activation of the NF-κB pathway. Taken together, SRR could mitigate IL-1β induced-cell dysfunction in human nucleus pulposus cells by regulating TGF-β1/NF-κB axis in vitro. Finally, the in vivo therapeutic effect of SRR on IVDD was confirmed. Our findings may contribute to the understanding of the complex interplay between inflammation and degenerative processes in the intervertebral disc and provide valuable insights into the development of targeted treatment-based therapeutics for IVDD.

| S-EPMC10620869 | biostudies-literature

Strontium Ranelate Elevates Expression of Heme Oxygenase-1 and Decreases Alveolar Bone Loss in Rats.

Project description:ObjectivesThe purpose of this study was to determine the effects of strontium ranelate on ligature-induced periodontitis in rats and assess the putative involvement of heme oxygenase-1 (HO-1) pathway in these effects.Material and methodsMale Wistar rats underwent nylon ligature placement around maxillary molars and were treated (v.o.) with strontium ranelate (20 or 100 mg/kg) for 7 days. After that, rats were euthanized and histomorphometric/histopathological analyses and RT-PCR for HO-1 expression were performed.ResultsStrontium ranelate (20 or 100 mg/kg) prevented bone resorption by 28% and 38%, respectively. Strontium ranelate treatment (100 mg/kg) up-regulated (P < 0.05) heme oxygenase-1 mRNA levels in the gingival tissues in comparison to control groups.ConclusionsStrontium ranelate prevented periodontal bone loss in experimental periodontitis in rats while heme oxygenase-1 mRNA levels increased after treatment.

| S-EPMC6365880 | biostudies-literature

Strontium disodium hexa-thio-diphosphate(IV) octa-hydrate.

Project description:The crystal structure of SrNa(2)(P(2)S(6))·8H(2)O is isotypic with that of its calcium analogue. The asymmetric unit consists of one Sr(2+) cation (2 symmetry), two Na(+) cations (2 and symmetry, respectively), one-half of a centrosymmetric (P(2)S(6))(4-) anion with a staggered confirmation and four water mol-ecules. The crystal structure is built up from layers of cations and anions extending parallel to (101). Each SrO(8) polyhedron is connected via edge-sharing to two NaO(4)S(2) octa-hedra and to one NaO(2)S(4) octa-hedron. The NaO(4)S(2) octa-edra are, in turn, connected with two (P(2)S(6))(4-) anions through common corners. Adjacent layers are held together by several O-H⋯S hydrogen-bonding inter-actions.

| S-EPMC3007201 | biostudies-literature

Strontium ranelate enriched Ruminococcus albus in the gut microbiome of Sprague-Dawley rats with postmenopausal osteoporosis.

Project description:BackgroundGut microbiome is critical to our human health and is related to postmenopausal osteoporosis (PMO). Strontium ranelate (SrR) is an anti-osteoporosis oral drug that can promote osteoblast formation and inhibit osteoclast formation. However, the effect of SrR on gut microbiome has been rarely studied. Therefore, we investigated the effect of oral SrR on gut microbiome and metabolic profiles.ResultsIn this study, we used ovariectomized (OVX) Sprague-Dawley rats to construct a PMO model and applied oral SrR for 6 weeks. The relative abundance of intestinal microbiome was investigated by 16S rRNA metagenomic sequencing. Ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) was used to analyze changes in metabolites of intestinal contents. Results demonstrated that 6-week oral SrR alleviated osteoporosis and significantly changed the composition of the gut microbiome and metabolic profiles of OVX rats. Ruminococcus, Akkermansia and Oscillospira were significantly enriched in the gut of OVX rats after 6-week oral SrR. Especially, the species R. albus showed the greatest importance by a random forest classifier between OVX and OVX_Sr group. The enrichment of R. albus in the gut was positively correlated with bone mineral density and the accumulation of lycopene and glutaric acid, which also significantly elevated after oral SrR.ConclusionsWe discovered that oral SrR can improve bone health while stimulate the accumulation of gut microbe R. albus and metabolites (lycopene and glutaric acid). The results suggested possible connections between oral SrR and the gut-bone axis, which may provide new insight into the treatment/prevention of osteoporosis.

| S-EPMC10680188 | biostudies-literature

Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model.

Project description:To investigate whether strontium ranelate (SR), a new antiosteoporotic agent, could attenuate cartilage degeneration and subchondral bone remodeling in osteoarthritis (OA).Medial meniscal tear (MMT) operation was performed in adult SD rats to induce OA. SR (625 or 1800 mg·kg(-1)·d(-1)) was administered via gavage for 3 or 6 weeks. After the animals were sacrificed, articular cartilage degeneration was evaluated using toluidine blue O staining, SOX9 immunohistochemistry and TUNEL assay. The changes in microarchitecture indices and tissue mineral density (TMD), chemical composition (mineral-to-collagen ratio), and intrinsic mechanical properties of the subchondral bones were measured using micro-CT scanning, confocal Raman microspectroscopy and nanoindentation testing, respectively.The high-dose SR significantly attenuated cartilage matrix and chondrocyte loss at 6 weeks, and decreased chondrocyte apoptosis, improved the expression of SOX9, a critical transcription factor responsible for the expression of anabolic genes type II collagen and aggrecan, at both 3 and 6 weeks. Meanwhile, the high-dose SR also significantly attenuated the subchondral bone remodeling at both 3 and 6 weeks, as shown by the improved microarchitecture indices, TMD, mineral-to-collagen ratio and intrinsic mechanical properties. In contrast, the low-dose SR did not significantly change all the detection indices of cartilage and bone at both 3 and 6 weeks.The high-dose SR treatment can reduce articular cartilage degeneration and subchondral bone remodeling in the rat MMT model of OA.

| S-EPMC4002491 | biostudies-other

Redetermination of hepta-potassium nona-hydrogen bis-[α-hexa-molybdoplatinate(IV)] undeca-hydrate.

Project description:Previously reported at a temperature of 298 (2) K [Lee & Joo (2007 ▶). Acta Cryst. E63, i11-i13], the title compound, K(7)[H(9)α-Pt(2)Mo(12)O(48)]·11H(2)O or K(7)[H(4.5)α-PtMo(6)O(24)](2)·11H(2)O, was redetermined at 146 (2) K in order to determine whether the H atom in the hydrogen bond that crosses the center of symmetry was located at the center of symmetry or disordered around it as assumed in the previous study. During the present low-temperature study it was found on the center of symmetry. One water molecule shows half-occupancy.

| S-EPMC2984051 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data